BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ekos Announces U.S. Enrollment Completion of the SEATTLE II Trial that Studies the Safety and Efficacy of Ultrasound Accelerated Thrombolysis for Treatment of Massive and Submassive Pulmonary Embolism


3/20/2013 10:38:08 AM

BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation, a privately held medical device company located in Bothell, Washington, announced today the completion of their second major trial for the treatment of pulmonary embolism (PE). The SEATTLE II study is a 150 patient single arm prospective study measuring the rapid reduction in right heart strain in a patient population with both massive and submassive PE. Robert W. Hubert, President and CEO of EKOS Corporation, cited U.S. patient statistics: “There are over 600,000 cases of PE each year alone of which upwards of 45% are considered major having significant clot in one or both pulmonary arteries. This clot burden interferes with the heart’s ability to pump blood into the lungs for oxygenation, causing enlargement of the right side of the heart. Not removing the clot burden quickly may result in permanent pulmonary hypertension or even death.”

Read at BioSpace.com

Ekos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES